Year Founded
2021
Ownership
Private
Employees
~10
Stage
Preclinical
Modalities
Small molecule

Asha Therapeutics General Information

Lead candidate ASHA-624 demonstrated robust neuroprotection and restored motor function in preclinical ALS models. Clinical trials anticipated to begin in early 2025.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Cincinnati, Ohio
United States

Drug Pipeline

ASHA-624
Pre-clinical
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Asha Therapeutics's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Asha Therapeutics Funding

Deal TypeDateAmountStatusStage
Later Stage VCJul 25, 2022$1.4MCompletedPreclinical
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Asha Therapeutics's complete valuation and funding history, request access »

Asha Therapeutics Investors

Includes grant funding from the ALS Association Barnett Drug Development Program.
Investor Type: Venture Capital
Holding: Minority
Other investors not specifically listed.
Investor Type: Venture Capital
Holding: Minority